Vor Biopharma Inc. (NASDAQ:VOR – Get Free Report)’s share price was down 5.4% during mid-day trading on Wednesday . The company traded as low as $23.59 and last traded at $23.7420. Approximately 192,494 shares changed hands during trading, a decline of 81% from the average session volume of 1,028,723 shares. The stock had previously closed at $25.10.
Analyst Upgrades and Downgrades
VOR has been the subject of a number of recent research reports. Wedbush lifted their price target on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price target on shares of Vor Biopharma in a report on Monday, May 18th. Wall Street Zen upgraded Vor Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings upgraded shares of Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $43.38.
Get Our Latest Research Report on VOR
Vor Biopharma Trading Down 5.3%
Vor Biopharma (NASDAQ:VOR – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). As a group, sell-side analysts forecast that Vor Biopharma Inc. will post -2.56 EPS for the current year.
Institutional Investors Weigh In On Vor Biopharma
Hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. boosted its holdings in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares during the period. XTX Topco Ltd bought a new position in shares of Vor Biopharma during the second quarter valued at approximately $66,000. Susquehanna Portfolio Strategies LLC purchased a new position in Vor Biopharma during the fourth quarter valued at approximately $134,000. Jane Street Group LLC bought a new stake in Vor Biopharma during the first quarter valued at about $140,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Vor Biopharma during the fourth quarter valued at about $141,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.
About Vor Biopharma
Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.
The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
Featured Stories
- Five stocks we like better than Vor Biopharma
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
- Lithia’s Record Quarter Keeps the Bull Case Alive
- 3 Lesser-Known Quantum Plays the Market May Be Overlooking Right Now
- Gold.com’s Q4 Results Show Why This Stock Is More Than a Gold Bet
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
